Global Hypertrophic Cardiomyopathy Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Hypertrophic Cardiomyopathy treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Algomedix Inc, C&C BioPharma LLC, Celltrion Pharmaceutical Inc, Cytokinetics, Lead Discovery Center GmbH and others.
A Significant contribution to the Hypertrophic Cardiomyopathy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Hypertrophic Cardiomyopathy pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Hypertrophic Cardiomyopathy condition and increased access to investments is encouraging growth of Hypertrophic Cardiomyopathy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Hypertrophic Cardiomyopathy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Hypertrophic Cardiomyopathy therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Hypertrophic Cardiomyopathy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Hypertrophic Cardiomyopathy. Further, orphan drug status, fast track designation, grants awarded and other special status for Hypertrophic Cardiomyopathy pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Hypertrophic Cardiomyopathy pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Hypertrophic Cardiomyopathy Pipeline candidates-
A Significant contribution to the Hypertrophic Cardiomyopathy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Hypertrophic Cardiomyopathy pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Hypertrophic Cardiomyopathy condition and increased access to investments is encouraging growth of Hypertrophic Cardiomyopathy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Hypertrophic Cardiomyopathy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Hypertrophic Cardiomyopathy therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Hypertrophic Cardiomyopathy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Hypertrophic Cardiomyopathy. Further, orphan drug status, fast track designation, grants awarded and other special status for Hypertrophic Cardiomyopathy pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Hypertrophic Cardiomyopathy pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Hypertrophic Cardiomyopathy Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Hypertrophic Cardiomyopathy drugs
- Late phase: Phase 3 and in-approval Hypertrophic Cardiomyopathy drugs
- Company overview
- Snapshot
- Hypertrophic Cardiomyopathy therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Hypertrophic Cardiomyopathy- Disease Overview
2.2 Hypertrophic Cardiomyopathy- Pipeline Snapshot
2.3 Hypertrophic Cardiomyopathy- Pipeline Drugs by Phase
2.4 Hypertrophic Cardiomyopathy- Pipeline Drugs by Company
2.5 Hypertrophic Cardiomyopathy- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Algomedix Inc Hypertrophic Cardiomyopathy Drug Pipeline, H2- 2019
3.2 C&C BioPharma LLC Hypertrophic Cardiomyopathy Drug Pipeline, H2- 2019
3.3 Celltrion Pharmaceutical Inc Hypertrophic Cardiomyopathy Drug Pipeline, H2- 2019
3.4 Cytokinetics Hypertrophic Cardiomyopathy Drug Pipeline, H2- 2019
3.5 Lead Discovery Center GmbH Hypertrophic Cardiomyopathy Drug Pipeline, H2- 2019
3.6 MyoKardia Inc Hypertrophic Cardiomyopathy Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Hypertrophic Cardiomyopathy- Phase 1 Drug Details
4.2 Hypertrophic Cardiomyopathy- Phase 1 Drug Overview
4.3 Hypertrophic Cardiomyopathy- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Hypertrophic Cardiomyopathy- Phase 2 Drug Details
5.2 Hypertrophic Cardiomyopathy- Phase 2 Drug Overview
5.3 Hypertrophic Cardiomyopathy- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Hypertrophic Cardiomyopathy- Phase 3 Drug Details
6.2 Hypertrophic Cardiomyopathy- Phase 3 Drug Overview
6.3 Hypertrophic Cardiomyopathy- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Hypertrophic Cardiomyopathy- Pre-clinical Phase Drug Details
7.2 Hypertrophic Cardiomyopathy- Pre-clinical Phase Drug Overview
7.3 Hypertrophic Cardiomyopathy- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Hypertrophic Cardiomyopathy- Disease Overview
2.2 Hypertrophic Cardiomyopathy- Pipeline Snapshot
2.3 Hypertrophic Cardiomyopathy- Pipeline Drugs by Phase
2.4 Hypertrophic Cardiomyopathy- Pipeline Drugs by Company
2.5 Hypertrophic Cardiomyopathy- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Algomedix Inc Hypertrophic Cardiomyopathy Drug Pipeline, H2- 2019
3.2 C&C BioPharma LLC Hypertrophic Cardiomyopathy Drug Pipeline, H2- 2019
3.3 Celltrion Pharmaceutical Inc Hypertrophic Cardiomyopathy Drug Pipeline, H2- 2019
3.4 Cytokinetics Hypertrophic Cardiomyopathy Drug Pipeline, H2- 2019
3.5 Lead Discovery Center GmbH Hypertrophic Cardiomyopathy Drug Pipeline, H2- 2019
3.6 MyoKardia Inc Hypertrophic Cardiomyopathy Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Hypertrophic Cardiomyopathy- Phase 1 Drug Details
4.2 Hypertrophic Cardiomyopathy- Phase 1 Drug Overview
4.3 Hypertrophic Cardiomyopathy- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Hypertrophic Cardiomyopathy- Phase 2 Drug Details
5.2 Hypertrophic Cardiomyopathy- Phase 2 Drug Overview
5.3 Hypertrophic Cardiomyopathy- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Hypertrophic Cardiomyopathy- Phase 3 Drug Details
6.2 Hypertrophic Cardiomyopathy- Phase 3 Drug Overview
6.3 Hypertrophic Cardiomyopathy- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Hypertrophic Cardiomyopathy- Pre-clinical Phase Drug Details
7.2 Hypertrophic Cardiomyopathy- Pre-clinical Phase Drug Overview
7.3 Hypertrophic Cardiomyopathy- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
